Application

Research Sub CategorySignaling Neuroscience

Anti-SET-beta, clone 3D10E2 is an antibody against SET-beta, clone 3D10E2 for use in Western Blotting.

Research CategoryNeuroscience

Western Blotting Analysis: 0.5 µg/mL from a representative lot detected SET-beta in 10 µg of LNCaP human prostate cancer cell lysate.
Western Blotting Analysis: 1.3 µg/mL from a representative lot specifically detected SET-beta, but not SET-alpha in Ramos human Burkitt′s lymphoma cell lysate (Courtesy of M. P. Vitek, Ph.D. Dr. Vitek is an employee and stockholder in Oncotide Pharmaceuticals, Inc. and a faculty member of Duke University Medical Center. Matters of potential personal and institutional conflict of interest are managed by the Duke University Medical Center Conflict of Interest Committee).

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Protein SET (UniProt Q01105; also known as HLA-DR-associated protein II, IGAAD, Inhibitor of granzyme A-activated DNase, PHAPII, I-2PP2A, Phosphatase 2A inhibitor I2PP2A, TAF-I, Template-activating factor I) is encoded by the SET gene (Gene ID 6418) in human. Protein SET (patient “SE translocation”) adopted its name when it was originally identified in a leukemia study in 1992. SET interacts with signaling pathways that promote normal cell growth and proliferation, as well as tumorigenesis and metastasis. SET protein inhibits PP2A by enhancing lyase activity of P450c17, a substrate for PP2A when it is Ser- and Thr-phosphorylated. Alternative splicings result in multiple SET isoforms, including SET-alpha (TAF-I alpha), SET-beta (TAF-I beta), and a shorter spliced Set-β isoform without the nuclear localization signal (NLS). Set-β functions have been described both in the nucleus and cytoplasm. The presence of a nuclear localization signal (NLS) and phosphorylation govern Set-β isoforms cellular localization. Proteolytic cleavage of Set-β at Lys176 by granzyme A or at Asn-175 by asparagine endopeptidase results in the release of GzmA-activated DNase (GAAD) from a multiprotein complex. Uninhibited in the absence of the full-length Set-β, GAAD causes cell death by its DNA-nicking activity.

Immunogen

KLH-conjugated linear peptide corresponding to a sequence near the N-terminus of human SET-beta.

Epitope: Near N-terminus.

Other Notes

Concentration: Please refer to lot specific datasheet.

Physical form

Purified mouse monoclonal IgG1κ antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Protein G purified.

Format: Purified

Quality

Evaluated by Western Blotting in DU145 cell lysate.

Western Blotting Analysis: 0.5 µg/mL of this antibody detected SET-beta in 10 µg of DU145 human prostate cancer cell lysate.

Specificity

Clone 3D10E2 recognizes an epitope sequence specific to the spliced isoform SET-beta (TAF-I beta) of human, murine, and rat species (UniProt Q01105-2, Q9EQU5-2, Q63945-2). The epitope sequence is not present in SET-alpha (TAF-I alpha) or any other human, murine, and rat protein SET spliced isoforms reported by UniProt.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Target description

~36 kDa observed. Band size appears larger than the calculated molecular weight of 31.97 kDa (Met1 removed) due to posttranslational modification (acetylation and/or phosphorylation).